There have been studies trying to identify potential soluble biomarkers such as suPAR (plasma-soluble urokinase plasminogen activator receptor) and EGFL7 (epidermal growth factor-like domain 7) for SSc-related complications [36, 37]. The gene discussed is EGFL7; the disease is systemic sclerosis.